Zobrazeno 1 - 10
of 36
pro vyhledávání: ''
Autor:
Chinthalapally V. Rao, Naveena B. Janakiram, Rebekah L. Ritchie, Vernon E. Steele, Altaf Mohammed, Stan Lightfoot, Laura Biddick, Venkateshwar Madka, Jagan M.R. Patlolla, Misty Brewer, Michael Sadeghi
Publikováno v:
Cancer Prevention Research. 7:1198-1209
Ornithine decarboxylase (ODC) is the key rate-limiting enzyme in the polyamine synthesis pathway and it is overexpressed in a variety of cancers. We found that polyamine synthesis and modulation of ODC signaling occurs at early stages of pancreatic p
Autor:
Weihua Shen, Sheng-Bin Peng, Baohui Zhao, Wenjuan Wu, William T. McMillen, Sajan Joseph, Jason Manro, Ramon V. Tiu, Shripad V. Bhagwat, Lisa Kindler, Jennifer R. Stephens
Publikováno v:
Cancer Research. 79:1307-1307
Pancreatic ductal adenocarcinoma (PDAC) is currently the third most frequent cause of cancer deaths in the US and is expected to be the second deadliest cancer by 2030. The 5-year survival rate in PDAC patients is only 6% and the poor prognosis is at
Autor:
Young Suk Park, Yoon-La Choi, Joon Oh Park, Hye Lim Jang, Seung Tae Kim, Do Hyoung Lim, Taekyu Lim, Kyung Kee Baek, Ho Yeong Lim, Won Ki Kang, Jeeyun Lee, Jun Ho Yi, Kee Taek Jang, Se Hoon Park
Publikováno v:
Molecular Cancer Therapeutics. 10:1993-1999
Although erlotinib has become an important therapeutic option in addition to gemcitabine, the high frequency of KRAS mutations in pancreatic cancer probably limits the benefits. We retrospectively studied 136 pancreatic cancer patients with available
Publikováno v:
Cancer Research. 78:PR12-PR12
Pancreatic ductal adenocarcinoma is a highly aggressive malignancy that is broadly resistant to both cytotoxic and targeted therapeutic agents. However, patients with BRCA2 mutations are reported to have improved responsiveness to certain chemotherap
Autor:
Joseph J. Cullen, Matthew Ough, Justine M. Ritchie, Marilyn M. Hinkhouse, Douglas R. Spitz, Ling Li, Anne Lewis
Publikováno v:
Clinical Cancer Research. 10:4550-4558
Purpose: NAD(P)H:quinone oxidoreductase (NQO1) catalyzes the two-electron reduction of quinones to hydroquinones. This reaction is believed to prevent the one-electron reduction of quinones that would result in redox cycling with generation of supero
Publikováno v:
Cancer Research. 77:4202-4202
Pancreatic ductal adenocarcinoma (PDAC) is currently the third leading cause of cancer related deaths in the USA with a 5-year survival less than 6%. Nanoparticle albumin-bound paclitaxel (nab-paclitaxel, NPT) has demonstrated 8.5 months median survi
Publikováno v:
Cancer Research. 77:LB-327
Pancreatic ductal adenocarcinoma (PDAC) still remains to be one of the most highly malignant human diseases and is resistant to the majority of current therapeutic modalities. Oncogene MYC has been known to be upregulated in PDAC and plays a key role
Autor:
Bissan Al-Lazikani, Johann S. de Bono, Adam Stewart, Parames Thavasu, Anguraj Sadanandam, Udai Banerji, Elizabeth A. Coker, Alexandros Georgiou, Anna Minchom, Timothy A. Yap
Publikováno v:
Cancer Research. 76:3099-3099
Background Clinical trials have shown that cancers originating from different tissues driven by the same oncogene respond differently to targeted anticancer drugs. We aimed to understand different signaling patterns in KRAS mutant cells derived from
Publikováno v:
Cancer Research. 76:665-665
Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of cancer mortality in the USA with approximately 50 000 new cases and 40 000 deaths in 2015.The 5-year survival rate has remained at 5% for the past three decades and the median sur
Autor:
David A. Proia, Ilya G. Serebriiskii, Elena Lysenko, Natalia Beglyarova, Vladimir Khazak, Natalia Skobeleva, Louis M. Weiner, Eugenia Banina, Igor Astsaturov, Sandra A. Jablonski
Publikováno v:
Cancer Research. 75:1465-1465
Pancreatic cancer (PDAC) affects 44,000 individuals yearly in the US. This cancer is almost universally lethal, with a very limited efficacy of approved chemotherapy (gemcitabine, nab-paclitaxel, platinum, 5FU). Clinical trials seeking to expand the